Arcutis Biotherapeutics, Inc.
ARQT
Rank in Stocks
#4007
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Share Price
$32.29
Last synced: 2026-10-19
Market Cap
$4.06B
Change (1 day)
12.02%
Change (1 year)
54.62%
Country
US
Trade Arcutis Biotherapeutics, Inc. (ARQT)
Category
Healthcare
P/S ratio for Arcutis Biotherapeutics, Inc. (ARQT)
P/S ratio as of October 2026 TTM: 7.15
According to Arcutis Biotherapeutics, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 7.15. At the end of 2023 the company had a P/S ratio of 3.76.
P/S ratio history for Arcutis Biotherapeutics, Inc. from 2017 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| 2026 (TTM) | 7.15 | -16.55% |
| 2024 | 8.57 | 128.27% |
| 2023 | 3.76 | -98.30% |
| 2022 | 220.96 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 10.02 | 40.14% |
US
|
|
| 40.55 | 467.01% |
US
|
|
| 3.96 | -44.61% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 41.87% |
NL
|
